Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 5, 1996, Pages 459-465

  Robert, Francisco ^a   Chen, Shande ^b   Miller, Antonius A ^c,d   Lee, Beverly C ^e   Molthrop, David C ^f,g   Wheeler, Richard H ^f,g  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e BIRMINGHAM VA MEDICAL CENTER   (United States)

^f University of Alabama at Birmingham   (United States)

^g Department of Pharmacology and Toxicology and Mass Spectrometry Core Facility   (United States)

Author keywords

Chemotherapy; Etoposide infusion

Indexed keywords

ETOPOSIDE;

ADVANCED CANCER; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CREATININE; ETOPOSIDE; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; INFUSION PUMPS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MOUTH MUCOSA; NEOPLASMS; STATISTICS, NONPARAMETRIC; STOMATITIS;

EID: 0029743185     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050511     Document Type: Article

References (31)

1. Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE (1987) Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 47:1952
2. Budmun DR, Igwemezie LN, Kaul S, Behr J, Lichtman S, Schulman P, Vinciguerra, Allen SL, Kolitz J, Hock K, O'Neil K, Schacter L, Barbhaiya RH (1994) Phase I evaluation of a watersoluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1,3 and 5 in patients with solid tumors. J Clin Oncol 12:1902
3. Cavalli F, Sonntag RW, Jungi F (1978) VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 62:473
4. Clark PI, Slevin ML (1987) The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 12:223
5. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31
6. Desoize B, Marechal F, Cattan A (1990) Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumors. Br J Cancer 62:840
7. Dombernowsky P, Nissen NI (1973) Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP-16-213 (NSC-141540) in L1210 leukemia. Acta Pathol Microbiol Scand [A] 81:715
8. Finney DJ (1950) Statistical method in biological assay. Charles Griffin, London
9. Friedman SA, Raizner AE, Rosen H (1972) Functional defects in aging kidney. Ann Intern Med 76:41
10. Graybill FA (1976) Theory and application of the linear model. Wadsworth, Pacific Grove
11. Hainsworth JD, Johnson DH, Frazier SR, Greco FA (1989) Chronic daily administration of oral etoposide: a phase I trial. J Clin Oncol 7:396
12. Hainsworth JD, Johnson DH, Greco FA (1990) Chronic daily administration of oral etoposide in refractory lymphoma: a phase II trial. Eur J Cancer 26:818
13. Hande KR (1992) Etoposide pharmacology. Semin Oncol [Suppl] 19:3
14. Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH (1993) Bioavailability of low-dose oral etoposide. J Clin Oncol 11:374
15. Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD (1990) Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 8:1613
16. McLeod HL, Evans WE (1993) Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins. In: Workman P, Graham MA (eds) Pharmacokinetics and cancer chemotherapy. Cold Spring Harbor Laboratory Press, Plainview, New York, p 253
17. Miller AA, Tolley EA (1994) Predictive performance of a pharmacodynamic model for oral etoposide. Cancer Res 54:2080
18. Miller AA, Stewart CF, Tolley EA (1990) Clinical pharmacodynamics of continuous-infusion etoposide. Cancer Chemother Pharmacol 25:361
19. Miller AA, Tolley EA, Niell HB, Griffin JP, Mauer AM (1993) Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small cell lung cancer. J Clin Oncol 11:1179
20. Miller AB, Hoogstraten B, Staguet M (1981) Reporting results of cancer treatment. Cancer 47:207
21. Minami H, Shimokata K, Saka H, Saito H, Ando Y, Senda K, Nomura F, Sakai S (1993) Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. J Clin Oncol 11:1602
22. Postmus PE, Mulder NH, Sleijfer DT (1984) High-dose etoposide for refractory malignancies: a phase I study. Cancer Treat Rep 68:1471
23. Ratain MJ, Schilsky RL, Choi KE, Guarnieri C, Grimmer D, Vogelzang NJ, Senekjian E, Liebner MA (1989) Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 45:226
24. SAS Procedure Guide, version 6. 3rd edn (1990) SAS Institute. Cary, North Carolina
25. Sinkule JA, Hutson P, Hayes FA, Etcubanas E, Evans W (1984) Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. Cancer Res 44:3109
26. Slevin ML (1991) The clinical pharmacology of etoposide. Cancer [Suppl] 67:319
27. Stewart CF, Pieper JA, Arbuck SG, Evans WE (1989) Altered protein binding of etoposide in patients with cancer. Clin Pharmacol Ther 45:49
28. Stewart CF, Arbuck SG, Fleming RA, Evans WE (1991) Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 50:385
29. Thompson DS, Hainsworth JD, Hande KR, Holzmea MC, Greco FA (1993) Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms. A phase I/II study. J Clin Oncol 11:1322
30. Waits TM, Johnson DH, Hainsworth JD, Hande KR, Thomas M, Greco FA (1992) Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial. J Clin Oncol 10:292
31. Wilcoxon F (1945) Individual comparisons by ranking methods. Biometric 1:80